Figure 3.
Expression of CD33, CLEC12A, FLT3, and HAVCR2 in pediatric and adult hematopoietic progenitors. (A) Gating strategy used for definition of 7 different hematopoietic progenitors downstream of gating on cells (side scatter [SSC]-A vs forward scatter [FSC]-A), single cells (FSC-H vs FSC-A), and living cells (SSC-A vs viability dye): MLPs, MPPs, HSCs, common lymphoid progenitors (CLPs), megakaryocyte/erythroid progenitors (MEPs), GMPs, and CMPs. Additionally, monocytes were gated according to SSC-A vs CD45 gating. (B) FLT3 expression by percentage (top) and MFI ratio (bottom). (C) CLEC12A expression by percentage (top) and MFI ratio (bottom). (D) CD33 expression by percentage (top) and MFI ratio (bottom). (E) Percentage of hematopoietic progenitors expressing both CD33 and CLEC12A. (F) Percentage of hematopoietic progenitors expressing both CD33 and FLT3. (G) Percentage of hematopoietic progenitors expressing both CD33 and HAVCR2.

Expression of CD33, CLEC12A, FLT3, and HAVCR2 in pediatric and adult hematopoietic progenitors. (A) Gating strategy used for definition of 7 different hematopoietic progenitors downstream of gating on cells (side scatter [SSC]-A vs forward scatter [FSC]-A), single cells (FSC-H vs FSC-A), and living cells (SSC-A vs viability dye): MLPs, MPPs, HSCs, common lymphoid progenitors (CLPs), megakaryocyte/erythroid progenitors (MEPs), GMPs, and CMPs. Additionally, monocytes were gated according to SSC-A vs CD45 gating. (B) FLT3 expression by percentage (top) and MFI ratio (bottom). (C) CLEC12A expression by percentage (top) and MFI ratio (bottom). (D) CD33 expression by percentage (top) and MFI ratio (bottom). (E) Percentage of hematopoietic progenitors expressing both CD33 and CLEC12A. (F) Percentage of hematopoietic progenitors expressing both CD33 and FLT3. (G) Percentage of hematopoietic progenitors expressing both CD33 and HAVCR2.

Close Modal

or Create an Account

Close Modal
Close Modal